Herborium Group Expands Sales in United Kingom
June 16 2010 - 4:00PM
Marketwired
Herborium Group, Inc., (PINKSHEETS: HBRM) www.herborium.com, a
Botanical Therapeutics™ company, today announced that it will be
expanding the scope of its distribution arrangements with the
renowned direct marketer of male grooming products in the UK,
Mankind LLC. Initially, Mankind has distributed Herborium
proprietary, novel, herbal acne treatment AcnEase® in the UK and
some other European markets to an upscale male segment through
e-commerce as well as catalogue channels.
"As Mankind is presently expanding its target market to include
female consumers and is planning to move into the retail market in
the UK, AcnEase will also gain access to those lucrative markets.
With the UK market for natural based products estimated to be over
$25 billion, and close to $1 billion spent on natural cosmceuticals
including medicated skin care products, and with an assistance of
such an experienced partner as Mankind, Herborium capturing just a
fraction of this market should result in a substantial growth of
revenues," commented Dr. Agnes P. Olszewski, Herborium's CEO and
President.
The Dermatology Market Outlook for 2011 forecasts that,
collectively, the acne market is estimated to be $2.7 billion in
2011. The major dermatological indications included in this market
are acne, the largest segment, and rosacea, the fifth largest
segment, both of which are treated successfully by AcnEase. In
clinical studies AcnEase® has demonstrated up to 95% efficacy in
diminishing acne and improving skin condition.
About Herborium Group, Inc. Herborium
Group, Inc., a botanical therapeutics® company, focuses on
developing, licensing, and marketing proprietary, botanical based
medicinal products to consumers and healthcare professionals. The
Company business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses clinical
validation and a proactive regulatory strategy based on the FDA
Guidance for Industry: Botanical Drug Products (FDA Guidance 2004)
to establish and maintain a differential advantage. Herborium
harvests its therapeutic candidates from Traditional Chinese
Medicine and utilizes Western regulatory, clinical and marketing
strategies to successfully introduce the products to the Western
markets. The company secured a pipeline of botanical ingredients
based products in the areas of dermatological needs, Prostate
Health (BPH), Liver Diseases, Women's Health and selected sexual
disorders resulting from cardiovascular disease, use of
anti-depressants, surgical procedures, and other problems.
Herborium Group sells its products in the United States, the United
Kingdom, and continental Europe through a network of distributors,
specialty retailers, and e-commerce.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time they are issued, and we disclaim any
obligation to update or alter forward-looking statements as the
result of new information or future events. Adino Energy
Corporation urges investors to review the risks and uncertainties
contained within its filings with the Securities and Exchange
Commission.
Company Contact: Dr. Agnes P. Olszewski President &
CEO (201) 647-3757
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From May 2024 to Jun 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2023 to Jun 2024